Lexaria Bioscience Corp (LEXX) Stock Price, Quote & News

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 765 6424

Website: lexariabioscience.com

Address:

740 McCurdy Road, Suite 100, Kelowna, Canada

hovian Sep. 18 at 11:44 PM

$LEXX someone like it low... until got all our shares... then pop up...

0 · Reply

Makingmillions192 Sep. 18 at 2:04 PM

$LEXX Looking for another MTA before Human Study #7 prints

0 · Reply

Makingmillions192 Sep. 18 at 2:04 PM

$LEXX Yes healthy bottom getting put in. $5 🔜

0 · Reply

Makingmillions192 Sep. 18 at 1:30 PM

$LEXX $9,660,000 in cash on hand

0 · Reply

topstockalerts Sep. 17 at 9:26 PM

$LEXX not chasing, but definitely respecting the move

0 · Reply

Makingmillions192 Sep. 17 at 8:08 PM

$LEXX Lexaria’s intraday reversal to close at $3.29 (+6.30%) marks a critical turning point following a forced warrant-liquidation cascade. Key Takeaways from the Turnaround: Cash Floor Anchoring: Management officially confirmed ~$4.60/share in net cash ($7.9M fresh capital + treasury), killing the negative EV anomaly and setting a concrete valuation baseline. No 2026 Dilution: A formal pledge of zero additional equity/debt raises in 2026 hard-closes the dilution window, forcing short-hedges to cover. Pivot to BD: Management is actively shifting to transfer R&D costs onto partners via out-licensing deals. Catalysts Ahead: 1. Late Sept: Preclinical Animal Study #1 readout. 2. Mid-Oct–Mid-Nov: Unblinded Human Study #7 readout (master PK/tolerability catalyst). 3. Q4: Commercial MTA out-licensing conversion.

0 · Reply

Makingmillions192 Sep. 17 at 7:57 PM

$LEXX Why?

1 · Reply

aaaaas Sep. 17 at 7:47 PM

$LEXX it’s really sad, the product is something I would like to invest in but the company running it needs to be nuked and replaced with competent leadershup

0 · Reply

Makingmillions192 Sep. 17 at 7:00 PM

$LEXX Bottoming processes are never straight forward - but excellent place to buy. Added another 1,800 shares

0 · Reply

MSG8898 Sep. 17 at 7:00 PM

$LEXX no investor touches this stock 'cause they know this will crater soon. They ain't been able to give an update on the animal study yet (early September, lol), human study? You know it! Lol!

0 · Reply

Lexaria Bioscience updates financial position

Sep 17, 2026, 9:10 AM EDT - 2 days ago

Lexaria Updates Financial Position

Sep 9, 2026, 4:15 PM EDT - 10 days ago

Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds

Sep 9, 2026, 4:15 PM EDT - 10 days ago

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

2026-09-08T12:20:22.000Z - 12 days ago

Lexaria Bioscience announces exercise of warrants for $5.9M in proceeds

Sep 8, 2026, 8:00 AM EDT - 12 days ago

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Sep 8, 2026, 8:00 AM EDT - 12 days ago

Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds

Sep 4, 2026, 9:20 AM EDT - 15 days ago

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

2026-09-01T13:20:16.000Z - 18 days ago

Lexaria Bioscience receives $2.6M tax rebate payment

Sep 1, 2026, 9:15 AM EDT - 18 days ago

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Aug 24, 2026, 9:10 AM EDT - 26 days ago

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

2026-08-17T07:39:00.000Z - 4 weeks ago

Lexaria Bioscience enters MTA with PegBio

Aug 13, 2026, 9:00 AM EDT - 5 weeks ago

Lexaria Enters a Material Transfer Agreement With PegBio

Aug 13, 2026, 9:00 AM EDT - 5 weeks ago

Lexaria Enters a Material Transfer Agreement with PegBio

2026-08-03T14:05:24.000Z - 6 weeks ago

Lexaria Bioscience Corp trading resumes

2026-08-03T14:00:38.000Z - 6 weeks ago

Lexaria Bioscience Corp trading halted, volatility trading pause

2026-07-31T23:55:25.000Z - 7 weeks ago

Lexaria Bioscience Corp trading halted, news pending

2026-07-30T15:10:56.000Z - 7 weeks ago

Lexaria Bioscience announces effective date for reverse stock split

Jul 30, 2026, 11:00 AM EDT - 7 weeks ago

Lexaria Announces Effective Date for Reverse Stock Split

Jul 13, 2026, 7:00 AM EDT - 2 months ago

Lexaria Bioscience Quarterly report: Q3 2026

Jul 6, 2026, 9:10 AM EDT - 2 months ago

Lexaria Updates Business Development

2026-06-25T13:15:18.000Z - 2 months ago

Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing

NVO

Jun 25, 2026, 9:10 AM EDT - 2 months ago

Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule

Jun 25, 2026, 9:10 AM EDT - 2 months ago

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

2026-06-23T15:26:36.000Z - 2 months ago

Lexaria Bioscience begins dosing in animal study GLP-1-A26-1

Jun 23, 2026, 9:25 AM EDT - 2 months ago

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Jun 23, 2026, 9:25 AM EDT - 2 months ago

Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule

2026-06-17T13:42:22.000Z - 3 months ago

Lexaria Bioscience provides update on GLP-1 oral pill market

Jun 17, 2026, 9:25 AM EDT - 3 months ago

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

Jun 17, 2026, 9:25 AM EDT - 3 months ago

GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

2026-06-09T13:34:05.000Z - 3 months ago

Lexaria announces dosing completion in 2026 Animal Study 2

Jun 9, 2026, 9:25 AM EDT - 3 months ago

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Jun 9, 2026, 9:25 AM EDT - 3 months ago

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Jun 3, 2026, 9:25 AM EDT - 3 months ago

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Jun 3, 2026, 9:25 AM EDT - 3 months ago

Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program

May 27, 2026, 7:00 AM EDT - 3 months ago

Lexaria Bioscience Slides: Corporate presentation

2026-05-19T13:27:07.000Z - 4 months ago

Lexaria Bioscience announces ethics approval for Human Pilot Study 7

NVO

May 19, 2026, 9:15 AM EDT - 4 months ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

May 7, 2026, 9:25 AM EDT - 4 months ago

Lexaria Bioscience Releases Second Episode of Investor Video Series

2026-05-05T13:24:25.000Z - 4 months ago

Lexaria Bioscience provides update on Human Pilot Study #7

NVO

May 5, 2026, 9:10 AM EDT - 4 months ago

Lexaria Updates Progress on Human Study #7

May 1, 2026, 9:25 AM EDT - 4 months ago

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

2026-04-29T13:16:24.000Z - 4 months ago

Lexaria Bioscience extends material transfer agreement with pharma company

Apr 29, 2026, 9:10 AM EDT - 4 months ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

2026-04-23T13:23:01.000Z - 4 months ago

Lexaria Bioscience launches new study to examine next-gen GLP-1 drugs

Apr 23, 2026, 9:05 AM EDT - 4 months ago

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

2026-04-21T15:02:42.000Z - 5 months ago

Lexaria Bioscience provides update on GLP-1 oral pill market

Apr 21, 2026, 9:10 AM EDT - 5 months ago

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

2026-04-15T13:24:10.000Z - 5 months ago

Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

Apr 15, 2026, 9:10 AM EDT - 5 months ago

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Apr 13, 2026, 8:00 AM EDT - 5 months ago

Lexaria Bioscience Quarterly report: Q2 2026

Apr 7, 2026, 9:10 AM EDT - 5 months ago

Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

Apr 1, 2026, 9:20 AM EDT - 5 months ago

Lexaria to Begin New Human Clinical Study in GLP-1

Mar 26, 2026, 9:20 AM EDT - 5 months ago

Lexaria's Robust Patent Portfolio Continues to Grow

Mar 24, 2026, 9:15 AM EDT - 5 months ago

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Mar 4, 2026, 9:25 AM EST - 6 months ago

Lexaria Announces New R&D Plans for 2026

Feb 5, 2026, 9:15 AM EST - 7 months ago

Lexaria Announces Positive Final Results From Human Pilot Study #5

Jan 22, 2026, 9:20 AM EST - 8 months ago

Lexaria Awarded Six Additional Patents

Jan 13, 2026, 7:00 AM EST - 8 months ago

Lexaria Bioscience Quarterly report: Q1 2026

Jan 12, 2026, 9:10 AM EST - 8 months ago

Lexaria Releases Annual Letter from the CEO

Dec 30, 2025, 9:20 AM EST - 8 months ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Dec 29, 2025, 7:00 AM EST - 8 months ago

Lexaria Bioscience Registration statement: Registration filing

Dec 23, 2025, 9:29 AM EST - 9 months ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 16, 2025, 4:00 PM EST - 9 months ago

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 9 months ago

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 10, 2025, 7:00 AM EST - 9 months ago

Lexaria Bioscience Proxy statement: Proxy filing

Dec 5, 2025, 7:00 AM EST - 9 months ago

Lexaria Bioscience Registration statement: Registration filing

Nov 28, 2025, 7:00 AM EST - 9 months ago

Lexaria Bioscience Annual report: Q4 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Lexaria Bioscience Registration statement: Registration filing

Oct 9, 2025, 9:20 AM EDT - 11 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Sep 29, 2025, 4:30 PM EDT - 11 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 11 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 19, 2025, 11:20 AM EDT - 1 year ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Aug 14, 2025, 9:20 AM EDT - 1 year ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 6, 2025, 9:20 AM EDT - 1 year ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

hovian Sep. 18 at 11:44 PM

$LEXX someone like it low... until got all our shares... then pop up...

0 · Reply

Makingmillions192 Sep. 18 at 2:04 PM

$LEXX Looking for another MTA before Human Study #7 prints

0 · Reply

Makingmillions192 Sep. 18 at 2:04 PM

$LEXX Yes healthy bottom getting put in. $5 🔜

0 · Reply

Makingmillions192 Sep. 18 at 1:30 PM

$LEXX $9,660,000 in cash on hand

0 · Reply

topstockalerts Sep. 17 at 9:26 PM

$LEXX not chasing, but definitely respecting the move

0 · Reply

Makingmillions192 Sep. 17 at 8:08 PM

0 · Reply

Makingmillions192 Sep. 17 at 7:57 PM

$LEXX Why?

1 · Reply

aaaaas Sep. 17 at 7:47 PM

$LEXX it’s really sad, the product is something I would like to invest in but the company running it needs to be nuked and replaced with competent leadershup

0 · Reply

Makingmillions192 Sep. 17 at 7:00 PM

$LEXX Bottoming processes are never straight forward - but excellent place to buy. Added another 1,800 shares

0 · Reply

MSG8898 Sep. 17 at 7:00 PM

$LEXX no investor touches this stock 'cause they know this will crater soon. They ain't been able to give an update on the animal study yet (early September, lol), human study? You know it! Lol!

0 · Reply

Makingmillions192 Sep. 17 at 6:57 PM

$LEXX Market giving a gift to buy down here before we continue our re-rate higher. 1h technicals cooling off - continued accumulation under the hood.

0 · Reply

MSG8898 Sep. 17 at 6:22 PM

$LEXX BTW, I loved how they seemed surprised of the share price collapsing, lol! Next warrant inducement ar 2$, mark my words!

2 · Reply

MSG8898 Sep. 17 at 6:15 PM

$LEXX come on, with such a great news, I would have thought at least 6$ per share, lol.

0 · Reply

Trade4Keeps Sep. 17 at 5:58 PM

$LEXX hopefully results will be better than $LGVN

0 · Reply

Makingmillions192 Sep. 17 at 4:43 PM

$LEXX

0 · Reply

Makingmillions192 Sep. 17 at 4:40 PM

$LEXX More than 50% of volume traded post raise is now under the current price and in the money. That was and still is the easiest buy. Heavy bids on lvl 2 ✅

0 · Reply

prismmarketview Sep. 17 at 4:10 PM

PRISM Mid-Day Movers: MedTech and Aerospace & Defense are Today’s leaders. Aethlon Medical, Inc. (NASDAQ: $AEMD ) surged up 383.22% to $6.91 in exceptionally active trading, with roughly 80.0 million shares changing hands versus average daily volume of about 1.1 million. Surf Air Mobility Inc. (NYSE: $SRFM ) jumped up 39.36% to $0.6926, moving between $0.5474 and $0.72 as volume reached roughly 34.6 million shares, more than six times its 5.6 million-share average. Other Notable Movers: Lexaria Bioscience ($LEXX ) up 23% Lisata Therapeutics ($LSTA ) up 22% Longeveron Inc. ($LGVN ) down -55% Stock prices and percentage changes are as of 12:00 p.m. ET on September 17, 2026, and are subject to change. https://prismmarketview.com/prism-mid-day-movers-medtech-and-aerospace-defense-are-todays-leaders-2/

0 · Reply

Makingmillions192 Sep. 17 at 2:33 PM

$LEXX Baseline of $5.50-6.50 is a fair short term target until updates on clinical studies and business development. Clear evidence of continued short unwinding / new positions being built. The hard part is over folks.

0 · Reply

Makingmillions192 Sep. 17 at 2:05 PM

$LEXX The biggest issue for this stock isn’t the science (which no bear will talk about). The biggest issue is that we haven’t had big pharma commercial validation yet. PegBio was a vote of confidence - but if they can secure a commercial deal which validates the platform than that is what takes us to a 50m mkt cap EASILY overnight. And they just hinted that is their plan. You don’t get outside pharma companies to foot the R&D bill without a commercial licensing deal. Hence the raise to bolster the balance sheet. If there was ever a time that required patience and buying the dip that time is now.

1 · Reply

MSG8898 Sep. 17 at 2:00 PM

$LEXX stock up with strong volume on a breaking news. Oh no, sorry, wrong ticker, lol. So, after a disastrous capital raise, the only news that came out is that cash on hand is basically all that was known, lol! They didn't even mind to suggest on what quarter cash on hand will last through. But hold it tight: no new capital raise in 2026, IMO we will have one in January. Lol!!!!

0 · Reply

Makingmillions192 Sep. 17 at 1:54 PM

$LEXX Whever the 4H has crossed over on the RSI and MACD following post raises the stock has already bottomed and typically was preparing for a big move up. As per the comments below by various users you can see a few small fishies wanted to short this lower. Unfortunately they missed the bottom and will provide a nice additional lift as we move up. Bought more this am. GLTA

0 · Reply

harlem111 Sep. 17 at 1:42 PM

$LEXX R and D...for 2027 RATS and DEATH . Did NOT hear we have a deal - just at best a slower burn rate for 2027. A much slower burn rate would be if Mgt salaries were tied to PPS. GLTA OU FOLKS DESERVE BETTER

0 · Reply

Market Cap	5.35M
Revenue (ttm)	710,000.00
Net Income (ttm)	-11.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,676.06%
Debt to Equity Ratio	0.00

Volume	76,300
Avg Vol	65,706
Day's Range	N/A - N/A
Shares Out	1.65M
Stochastic %K	5%
Beta	0.50
Analysts	Strong Sell
Price Target	$3.50